|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 48/00 | (2006.01) |
| C07H 21/02 | (2006.01) | ||
| C07H 21/04 | (2006.01) |
| (11) | Number of the document | 3682905 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19216461.4 |
| Date of filing the European patent application | 2012-10-03 | |
| (97) | Date of publication of the European application | 2020-07-22 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-01 |
| (46) | Date of publication of the claims translation | 2022-02-25 |
| (30) | Number | Date | Country code |
| 201161542533 P | 2011-10-03 | US |
| (72) |
De Fougerolles, Antonin , US
Roy, Atanu , US
Schrum, Jason P. , US
Siddiqi, Suhaib , US
Hatala, Paul , US
Bancel, Stephane , US
|
| (73) |
ModernaTX, Inc. ,
325 Binney Street, Cambridge, MA 02142,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas |
| MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2023-09-18 | 12 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-10-03 |